Drug Profile
Bimatoprost/brimonidine/timolol
Alternative Names: Bimatoprost/timolol/brimonidine; Timolol/brimonidine/bimatoprostLatest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Class Antiglaucomas; Antihypertensives; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists; Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glaucoma; Ocular hypertension
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 11 Sep 2018 No development reported - Phase-III for Glaucoma in Brazil, Mexico, Colombia, India (Ophthalmic, Drops)
- 11 Sep 2018 No development reported - Phase-III for Ocular hypertension in Brazil, Mexico, Colombia, India (Ophthalmic, Drops)